"variable_name","dataset","code_list","definition"
"budget_cpp_dstb","Budget",,"Average cost of drugs budgeted per patient for drug-susceptible TB treatment, excluding buffer stock (US Dollars)"
"budget_cpp_mdr","Budget",,"Average cost of drugs budgeted per patient for MDR-TB treatment, excluding buffer stock (US Dollars)"
"budget_cpp_tpt","Budget",,"Average cost of drugs budgeted per patient for  TB preventive treatment, excluding buffer stock (US Dollars)"
"budget_cpp_xdr","Budget",,"Average cost of drugs budgeted per patient for pre-XDR/XDR-TB treatment, excluding buffer stock (US Dollars)"
"budget_fld","Budget",,"Budget required for drugs to treat drug-susceptible TB (US Dollars)"
"budget_lab","Budget",,"Budget required for laboratory infrastructure, equipment and supplies (US Dollars)"
"budget_mdrmgt","Budget",,"Budget required for programme costs to treat drug-resistant TB (US Dollars)"
"budget_orsrvy","Budget",,"Budget required for operational research and surveys (US Dollars)"
"budget_oth","Budget",,"Budget required for all other budget line items (US Dollars)"
"budget_patsup","Budget",,"Budget required for patient support (US Dollars)"
"budget_prog","Budget",,"Budget required for programme costs to treat drug-susceptible TB (US Dollars)"
"budget_sld","Budget",,"Budget required for drugs to treat drug-resistant TB (US Dollars)"
"budget_staff","Budget",,"Budget required for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)"
"budget_tbhiv","Budget",,"Budget required for collaborative TB/HIV activities (US Dollars)"
"budget_tot","Budget",,"Total budget required (US Dollars)"
"budget_tpt","Budget",,"Budget required for TB preventive treatment: drugs (US Dollars)"
"cf_fld","Budget",,"Expected funding for drugs to treat drug-susceptible TB (US Dollars)"
"cf_lab","Budget",,"Expected funding for laboratory infrastructure, equipment and supplies (US Dollars)"
"cf_mdrmgt","Budget",,"Expected funding for programme costs to treat drug-resistant TB (US Dollars)"
"cf_orsrvy","Budget",,"Expected funding for operational research and surveys (US Dollars)"
"cf_oth","Budget",,"Expected funding for all other budget line items (US Dollars)"
"cf_patsup","Budget",,"Expected funding for patient support (US Dollars)"
"cf_prog","Budget",,"Expected funding for programme costs to treat drug-susceptible TB (US Dollars)"
"cf_sld","Budget",,"Expected funding for drugs to treat drug-resistant TB (US Dollars)"
"cf_staff","Budget",,"Expected funding for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)"
"cf_tbhiv","Budget",,"Expected funding for collaborative TB/HIV activities (US Dollars)"
"cf_tot","Budget",,"Total expected funding for all budget line items (US Dollars)"
"cf_tot_domestic","Budget",,"Expected funding from domestic sources, including loans (US Dollars)"
"cf_tot_gf","Budget",,"Expected funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)"
"cf_tot_grnt","Budget",,"Expected funding from other sources (US Dollars)"
"cf_tot_sources","Budget",,"Total expected funding from all sources (US Dollars)"
"cf_tot_usaid","Budget",,"Expected funding from USAID (US Dollars)"
"cf_tpt","Budget",,"Expected funding for TB preventive treatment drugs (US Dollars)"
"tx_dstb","Budget",,"Number of patients expected to start drug-susceptible TB treatment"
"tx_mdr","Budget",,"Number of patients expected to start MDR-TB treatment"
"tx_tpt","Budget",,"Number of patients expected to start TB preventive treatment"
"tx_xdr","Budget",,"Number of patients expected to start pre-XDR/XDR-TB treatment"
"bmu","Community engagement",,"Number of TB Basic Management Units in the country"
"bmu_community_impl","Community engagement",,"Number of TB Basic Management Units which implemented community-based referrals or any form of community treatment adherence support"
"bmu_ref_data","Community engagement",,"Number of Basic Management Units with data on referrals by community health workers / community volunteers"
"bmu_rxsupport_data","Community engagement",,"Number of Basic Management Units with data on community treatment adherence support"
"bmu_rxsupport_data_coh","Community engagement",,"Total number of patients who started TB treatment in the Basic Management Units with data on community treatment adherence support"
"community_data_available","Community engagement","0=No; 1=Yes","Are data available on community-based referrals or any form of community treatment adherence support?"
"notified_ref","Community engagement",,"Total number of new and relapse TB cases notified in the Basic Management Units with data on referrals by community health workers"
"notified_ref_community","Community engagement",,"Total number of new and relapse TB cases referred by community health workers / community volunteers in the Basic Management Units with data on referrals by community health workers"
"rxsupport_community_coh","Community engagement",,"Total number of patients who started TB treatment and who received any form of treatment adherence support from community health workers / community volunteers in the Basic Management Units with data on community treatment adherence support"
"rxsupport_community_succ","Community engagement",,"Total number of patients who were cured or who completed treatment among the cases who started TB treatment and who received any form of treatment adherence support from community health workers / community volunteers in the Basic Management Units with data on community treatment adherence support"
"newinc_con","Contacts preventive treatment",,"(If screen_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases"
"newinc_con_prevtx","Contacts preventive treatment",,"(If prevtx_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases notified in the reporting year who were started on TB preventive treatment"
"newinc_con_prevtx_cmplt","Contacts preventive treatment",,"Among household contacts reported in newinc_con_prevtx, number who completed the course of TB preventive treatment"
"newinc_con_screen","Contacts preventive treatment",,"(If screen_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases who were evaluated for active TB and latent TB"
"newinc_con_tb","Contacts preventive treatment",,"(If screen_data_available=60) Number of household contacts of bacteriologically confirmed pulmonary new and relapse TB cases who were diagnosed with TB disease"
"newinc_con04_prevtx","Contacts preventive treatment",,"(If prevtx_data_available=60) Number of children aged under 5 started on TB preventive treatment who are household contacts of bacteriologically-confirmed new and relapse TB cases notified"
"newinc_con5plus_prevtx","Contacts preventive treatment",,"(If prevtx_5plus_data_available=60 and year=2017) Number of children aged 5 years and above, adolescents and adults started on TB preventive therapy who are household contacts of bacteriologically-confirmed new and relapse TB cases notified"
"prevtx_5plus_data_available","Contacts preventive treatment","0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population","(for year=2017 only) Are data available on the number of children aged 5 years and above, adolescents and adults who are household contacts of TB cases and started on TB preventive therapy?"
"prevtx_data_available","Contacts preventive treatment","0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population","Are data available on the number of household contacts of TB cases started on TB preventive treatment?"
"prevtx_short_data_available","Contacts preventive treatment","0=No; 1=Yes; 2=Not applicable; 194=Not used","Are data available on the number of patients treated using shorter TB preventive treatment regimens containing rifampicin or rifapentine?"
"prevtx_short_rifamycin","Contacts preventive treatment",,"(if prevtx_short_data_available=1) Total number of individuals started on shorter TB preventive treatment regimens containing rifampicin or rifapentine in the reporting year"
"ptsurvey_newinc","Contacts preventive treatment",,"(If prevtx_data_available=61) Number of bacteriologically-confirmed TB new and relapse cases notified in the reporting year whose medical records or treatment cards were included in a survey"
"ptsurvey_newinc_5plus","Contacts preventive treatment",,"(If prevtx_5plus_data_available=61 and year=2017) Number of bacteriologically-confirmed TB new and relapse cases notified in the reporting year whose medical records or treatment cards were included in a survey"
"ptsurvey_newinc_con_prevtx","Contacts preventive treatment",,"(If prevtx_data_available=61) Number of household contacts of the TB cases surveyed in ptsurvey_newinc who were started on TB preventive treatment."
"ptsurvey_newinc_con04_prevtx","Contacts preventive treatment",,"(If prevtx_data_available=61) Number of children aged under 5 started on TB preventive treatment who are household contacts of the TB cases in ptsurvey_newinc"
"ptsurvey_newinc_con5plus_prevtx","Contacts preventive treatment",,"(If prevtx_5plus_data_available=61 and year=2017) Number of children aged 5 years and above, adolescents and adults started on TB preventive therapy who are household contacts of the TB cases in ptsurvey_newinc_5plus"
"rev_newinc","Contacts preventive treatment",,"(If screen_data_available=61) Number of bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review"
"rev_newinc_con","Contacts preventive treatment",,"(If screen_data_available=61) Number of household contacts identified from the bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review"
"rev_newinc_con_screen","Contacts preventive treatment",,"(If screen_data_available=61) Number of household contacts who were evaluated for active TB and latent TB identified from the bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review"
"rev_newinc_con_tb","Contacts preventive treatment",,"(If screen_data_available=61) Number of household contacts of bacteriologically confirmed pulmonary new and relapse TB cases who were diagnosed with TB disease and whose medical records or treatment cards were included in the review"
"screen_data_available","Contacts preventive treatment","0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records or treatment cards of TB patients representative of the national TB patient population; 5=Not applicable","Are data available on the number of household contacts of TB cases who were evaluated for TB?"
"tpt_1hp","Contacts preventive treatment","0=No; 1=Yes; 3=Don't know;","(If tpt_short_regimens_used=1) Was the 1 month daily rifapentine and isoniazid (1HP) TB preventive treatment regimen used at least once?"
"tpt_3hp","Contacts preventive treatment","0=No; 1=Yes; 3=Don't know;","(If tpt_short_regimens_used=1) Was the 3 month weekly rifapentine and isoniazid (3HP) TB preventive treatment regimen used at least once?"
"tpt_3hr","Contacts preventive treatment","0=No; 1=Yes; 3=Don't know;","(If tpt_short_regimens_used=1) Was the 3 month daily rifampicin and isoniazid (3HR) TB preventive treatment regimen used at least once?"
"tpt_4r","Contacts preventive treatment","0=No; 1=Yes; 3=Don't know;","(If tpt_short_regimens_used=1) Was the 4 month daily rifampicin (4R) TB preventive treatment regimen used at least once?"
"tpt_short_regimens_used","Contacts preventive treatment","0=No; 1=Yes; 3=Don't know;","Were any shorter TB preventive treatment regimes containing rifampicin or rifapentine used at least once?"
"country","Country identification",,"Country or territory name"
"g_whoregion","Country identification","AFR=Africa; AMR=Americas; EMR=Eastern Mediterranian; EUR=Europe; SEA=South-East Asia; WPR=Western Pacific","WHO region"
"iso_numeric","Country identification",,"ISO numeric country/territory code"
"iso2","Country identification",,"ISO 2-character country/territory code"
"iso3","Country identification",,"ISO 3-character country/territory code"
"age_group","Disaggregated estimates","0-4=0-4 years; 5-14=5-14 years; 15-24=15-24 years ..etc; 15plus=15 years and above; 65plus=65 years and above; all=All ages;","Age group (in years)"
"best","Disaggregated estimates",,"Best estimate"
"hi","Disaggregated estimates",,"High bound of estimate"
"lo","Disaggregated estimates",,"Low bound of estimate"
"measure","Disaggregated estimates","inc = incidence","The measure of TB burden being estimated"
"risk_factor","Disaggregated estimates","alc=Harmful use of alcohol; dia=Diabetes; hiv=HIV; smk=Smoking; und=Undernourishment; all=All (not disaggregated by specific risk factors)","Cases attributable to a specific risk factor"
"sex","Disaggregated estimates","a=All (females and males); f=Females; m=Males","Sex"
"unit","Disaggregated estimates","num=absolute number","The unit of measurement"
"dst_rlt_hr_new","Drug resistance surveillance",,"Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to isoniazid (regardless of result for rifampicin)"
"dst_rlt_hr_ret","Drug resistance surveillance",,"Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to isoniazid (regardless of result for rifampicin)"
"dst_rlt_new","Drug resistance surveillance",,"Drug resistance surveillance: Among new pulmonary TB patients with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicin"
"dst_rlt_ret","Drug resistance surveillance",,"Drug resistance surveillance: Among patients previously treated for TB with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicin"
"dst_rlt_rr_new","Drug resistance surveillance",,"Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid)"
"dst_rlt_rr_ret","Drug resistance surveillance",,"Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid)"
"mdr_dst_rlt","Drug resistance surveillance",,"Drug resistance surveillance: Total number of pulmonary MDR-TB patients with drug susceptibility test results for any fluoroquinolone and any second-line injectable agent"
"mdr_new","Drug resistance surveillance",,"Drug resistance surveillance: Among new TB patients with available drug susceptibility testing results (variable dst_rlt_new):  number of patients with resistance to isoniazid and rifampicin  (MDR-TB)"
"mdr_ret","Drug resistance surveillance",,"Drug resistance surveillance: Among patients previously treated for TB with available drug susceptibility testing results (variable dst_rlt_ret):  number of patients with resistance to isoniazid and rifampicin  (MDR-TB)"
"nrr_014","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are aged 0-14 years"
"nrr_15plus","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are aged 15 years and over"
"nrr_ageunk","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and whose age is unknown"
"nrr_hivneg","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are HIV-negative"
"nrr_hivpos","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are HIV-positive"
"nrr_hivunk","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and whose HIV status is unknown"
"pulm_labconf_new","Drug resistance surveillance",,"Number of new bacteriologically confirmed pulmonary TB cases"
"pulm_labconf_ret","Drug resistance surveillance",,"Number of previously treated bacteriologically confirmed pulmonary TB cases"
"pulm_labconf_unk","Drug resistance surveillance",,"Number of bacteriologically confirmed pulmonary TB cases with unknown TB treatment history"
"r_rlt_new","Drug resistance surveillance",,"Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin"
"r_rlt_rel","Drug resistance surveillance",,"Number of bacteriologically confirmed pulmonary relapse TB patients with test results for rifampicin"
"r_rlt_ret","Drug resistance surveillance",,"Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin"
"rr_014","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are aged 0-14 years"
"rr_15plus","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are aged 15 years and over"
"rr_ageunk","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and whose age is unknown"
"rr_dr_2li","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to second-line injectable agents"
"rr_dr_fq","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to fluoroquinolones"
"rr_dr_fq_2li","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to both fluoroquinolones and second-line injectable agents"
"rr_ds_fq2li","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and susceptible to both fluoroquinolones and second-line injectable agents"
"rr_dst_rlt","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and with test results for any fluoroquinolone and any second-line injectable agent"
"rr_dst_rlt_fq","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and with test results for any fluoroquinolone"
"rr_fqr","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to fluoroquinolones"
"rr_fqr_bdqr_lzdr","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones, bedaquiline and linezolid."
"rr_fqr_bdqr_lzds","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and bedaquiline but susceptible to linezolid."
"rr_fqr_bdqr_lzdu","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and bedaquiline but unknown resistance to linezolid."
"rr_fqr_bdqs_lzdr","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and linezolid, but susceptible to bedaquiline."
"rr_fqr_bdqs_lzds","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones but susceptible to bedaquiline and linezolid."
"rr_fqr_bdqs_lzdu","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and fluoroquinolones, but susceptible to bedaquiline and with unknown resistance to linezolid."
"rr_fqr_bdqu_lzdr","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and linezolid, but unknown resistance to bedaquiline."
"rr_fqr_bdqu_lzds","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones but susceptible to linezolid and unknown resistance to bedaquiline."
"rr_fqr_bdqu_lzdu","Drug resistance surveillance",,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and fluoroquinolones, but with unknown resistance to bedaquiline and linezolid."
"rr_hivneg","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are HIV-negative"
"rr_hivpos","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are HIV-positive"
"rr_hivunk","Drug resistance surveillance",,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and whose HIV status is unknown"
"rr_new","Drug resistance surveillance",,"Number of new bacteriologically confirmed pulmonary TB patients with resistance to rifampicin (RR-TB)"
"rr_rel","Drug resistance surveillance",,"Number of bacteriologically confirmed pulmonary relapse TB patients  with resistance to rifampicin (RR-TB)"
"rr_ret","Drug resistance surveillance",,"Number of previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin (RR-TB)"
"xdr","Drug resistance surveillance",,"Drug resistance surveillance: Among pulmonary MDR-TB patients with drug susceptibility test results for any fluoroquinolone (FQ) and any second-line injectable agent (2LI) (variable mdr_dst_rlt): number with any resistance to both FQ and 2LI (i.e. XDR-TB in pre-2020 definitions)"
"c_cdr","Estimates",,"Case detection rate (all forms) [also known as TB treatment coverage], percent"
"c_cdr_hi","Estimates",,"Case detection rate (all forms) [also known as TB treatment coverage], percent, high bound"
"c_cdr_lo","Estimates",,"Case detection rate (all forms) [also known as TB treatment coverage], percent, low bound"
"c_newinc_100k","Estimates",,"Case notification rate, which is the total of new and relapse cases and cases with unknown previous TB treatment history per 100 000 population (calculated)"
"cfr","Estimates",,"Estimated TB case fatality ratio"
"cfr_hi","Estimates",,"Estimated TB case fatality ratio: high bound"
"cfr_lo","Estimates",,"Estimated TB case fatality ratio: low bound"
"cfr_pct","Estimates",,"Estimated TB case fatality ratio expressed as a percentage"
"cfr_pct_hi","Estimates",,"Estimated TB case fatality ratio: high bound expressed as a percentage"
"cfr_pct_lo","Estimates",,"Estimated TB case fatality ratio: low bound expressed as a percentage"
"e_inc_100k","Estimates",,"Estimated incidence (all forms) per 100 000 population"
"e_inc_100k_hi","Estimates",,"Estimated incidence (all forms) per 100 000 population, high bound"
"e_inc_100k_lo","Estimates",,"Estimated incidence (all forms) per 100 000 population, low bound"
"e_inc_num","Estimates",,"Estimated number of incident cases (all forms)"
"e_inc_num_hi","Estimates",,"Estimated number of incident cases (all forms), high bound"
"e_inc_num_lo","Estimates",,"Estimated number of incident cases (all forms), low bound"
"e_inc_rr_num","Estimates",,"Estimated incidence of rifampicin resistant TB (absolute number)"
"e_inc_rr_num_hi","Estimates",,"Estimated incidence of rifampicin resistant TB (absolute number): high bound"
"e_inc_rr_num_lo","Estimates",,"Estimated incidence of rifampicin resistant TB (absolute number): low bound"
"e_inc_tbhiv_100k","Estimates",,"Estimated incidence of TB cases who are HIV-positive per 100 000 population"
"e_inc_tbhiv_100k_hi","Estimates",,"Estimated incidence of TB cases who are HIV-positive per 100 000 population, high bound"
"e_inc_tbhiv_100k_lo","Estimates",,"Estimated incidence of TB cases who are HIV-positive per 100 000 population, low bound"
"e_inc_tbhiv_num","Estimates",,"Estimated incidence of TB cases who are HIV-positive"
"e_inc_tbhiv_num_hi","Estimates",,"Estimated incidence of TB cases who are HIV-positive, high bound"
"e_inc_tbhiv_num_lo","Estimates",,"Estimated incidence of TB cases who are HIV-positive, low bound"
"e_mort_100k","Estimates",,"Estimated mortality of TB cases (all forms) per 100 000 population"
"e_mort_100k_hi","Estimates",,"Estimated mortality of TB cases (all forms) per 100 000 population, high bound"
"e_mort_100k_lo","Estimates",,"Estimated mortality of TB cases (all forms) per 100 000 population, low bound"
"e_mort_exc_tbhiv_100k","Estimates",,"Estimated mortality of TB cases (all forms, excluding HIV) per 100 000 population"
"e_mort_exc_tbhiv_100k_hi","Estimates",,"Estimated mortality of TB cases (all forms, excluding HIV), per 100 000 population, high bound"
"e_mort_exc_tbhiv_100k_lo","Estimates",,"Estimated mortality of TB cases (all forms, excluding HIV), per 100 000 population, low bound"
"e_mort_exc_tbhiv_num","Estimates",,"Estimated number of deaths from TB (all forms, excluding HIV)"
"e_mort_exc_tbhiv_num_hi","Estimates",,"Estimated number of deaths from TB (all forms, excluding HIV), high bound"
"e_mort_exc_tbhiv_num_lo","Estimates",,"Estimated number of deaths from TB (all forms, excluding HIV), low bound"
"e_mort_num","Estimates",,"Estimated number of deaths from TB (all forms)"
"e_mort_num_hi","Estimates",,"Estimated number of deaths from TB (all forms), high bound"
"e_mort_num_lo","Estimates",,"Estimated number of deaths from TB (all forms), low bound"
"e_mort_tbhiv_100k","Estimates",,"Estimated mortality of TB cases who are HIV-positive, per 100 000 population"
"e_mort_tbhiv_100k_hi","Estimates",,"Estimated mortality of TB cases who are HIV-positive, per 100 000 population, high bound"
"e_mort_tbhiv_100k_lo","Estimates",,"Estimated mortality of TB cases who are HIV-positive, per 100 000 population, low bound"
"e_mort_tbhiv_num","Estimates",,"Estimated number of deaths from TB in people who are HIV-positive"
"e_mort_tbhiv_num_hi","Estimates",,"Estimated number of deaths from TB in people who are HIV-positive, high bound"
"e_mort_tbhiv_num_lo","Estimates",,"Estimated number of deaths from TB in people who are HIV-positive, low bound"
"e_pop_num","Estimates",,"Estimated total population number"
"e_rr_in_notified_labconf_pulm","Estimates",,"Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases"
"e_rr_in_notified_labconf_pulm_hi","Estimates",,"Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases: high bound"
"e_rr_in_notified_labconf_pulm_lo","Estimates",,"Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases: low bound"
"e_rr_pct_new","Estimates",,"Estimated percentage of new TB cases with rifampicin resistant TB"
"e_rr_pct_new_hi","Estimates",,"Estimated percentage of new TB cases with rifampicin resistant TB: high bound"
"e_rr_pct_new_lo","Estimates",,"Estimated percentage of new TB cases with rifampicin resistant TB: low bound"
"e_rr_pct_ret","Estimates",,"Estimated percentage of previously treated TB cases with rifampicin resistant TB"
"e_rr_pct_ret_hi","Estimates",,"Estimated percentage of previously treated TB cases with rifampicin resistant TB: high bound"
"e_rr_pct_ret_lo","Estimates",,"Estimated percentage of previously treated TB cases with rifampicin resistant TB: low bound"
"e_tbhiv_prct","Estimates",,"Estimated HIV in incident TB (percent)"
"e_tbhiv_prct_hi","Estimates",,"Estimated HIV in incident TB (percent), high bound"
"e_tbhiv_prct_lo","Estimates",,"Estimated HIV in incident TB (percent), low bound"
"source_rr_new","Estimates",,"Method used to estimate proportion of new TB patients with rifampicin-resistant TB"
"source_rr_ret","Estimates",,"Method used to estimate proportion of previously treated TB patients with rifampicin-resistant TB"
"exp_cpp_dstb","Expenditure and utilisation",,"Average cost of drugs spent per patient starting first-line TB treatment, excluding buffer stock (US Dollars)"
"exp_cpp_mdr","Expenditure and utilisation",,"Average cost of drugs spent per patient starting second-line treatment for MDR-TB, excluding buffer stock (US Dollars)"
"exp_cpp_tpt","Expenditure and utilisation",,"Average cost of drugs spent per person starting TB preventive treatment, excluding buffer stock (US Dollars)"
"exp_cpp_xdr","Expenditure and utilisation",,"Average cost of drugs spent per patient starting pre-XDR/XDR-TB treatment, excluding buffer stock (US Dollars)"
"exp_fld","Expenditure and utilisation",,"Actual expenditure on drugs to treat drug-susceptible TB (US Dollars)"
"exp_lab","Expenditure and utilisation",,"Actual expenditure on laboratory infrastructure, equipment and supplies (US Dollars)"
"exp_mdrmgt","Expenditure and utilisation",,"Actual expenditure on programme costs to treat drug-resistant TB (US Dollars)"
"exp_orsrvy","Expenditure and utilisation",,"Actual expenditure on operational research and surveys (US Dollars)"
"exp_oth","Expenditure and utilisation",,"Actual expenditure on all other budget line items (US Dollars)"
"exp_patsup","Expenditure and utilisation",,"Actual expenditure on patient support (US Dollars)"
"exp_prog","Expenditure and utilisation",,"Actual expenditure on programme costs to treat drug-susceptible TB (US Dollars)"
"exp_sld","Expenditure and utilisation",,"Actual expenditure on drugs to treat drug-resistant TB (US Dollars)"
"exp_staff","Expenditure and utilisation",,"Actual expenditure on National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)"
"exp_tbhiv","Expenditure and utilisation",,"Actual expenditure on collaborative TB/HIV activities (US Dollars)"
"exp_tot","Expenditure and utilisation",,"Total actual expenditure (US Dollars)"
"exp_tpt","Expenditure and utilisation",,"Actual expenditure on drugs for TB preventive treatment (US Dollars)"
"hcfvisit_dstb","Expenditure and utilisation",,"Typical number of visits to a health facility after diagnosis for patients starting first-line TB treatment"
"hcfvisit_mdr","Expenditure and utilisation",,"Typical number of visits to a health facility after diagnosis for patients starting MDR-TB/XDR-TB treatment"
"hosp_type_mdr","Expenditure and utilisation","2=Not applicable; 140=Primary-level hospital; 141=Secondary-level hospital; 142= Tertiary-level hospital","Type of facility most often used if MDR-TB patients are hospitalized"
"hospd_dstb_dur","Expenditure and utilisation",,"Estimated average duration of stay if patients starting first-line TB treatment are hospitalized (days)"
"hospd_dstb_prct","Expenditure and utilisation",,"Estimated percentage of patients starting first-line TB treatment that are hospitalized (%)"
"hospd_mdr_dur","Expenditure and utilisation",,"Estimated average duration of stay if patients starting MDR-TB/XDR-TB treatment are hospitalized (days)"
"hospd_mdr_prct","Expenditure and utilisation",,"Estimated percentage of patients starting MDR-TB/XDR-TB treatment that are hospitalized (%)"
"rcvd_fld","Expenditure and utilisation",,"Funding received for drugs to treat drug-susceptible TB (US Dollars)"
"rcvd_lab","Expenditure and utilisation",,"Funding received for laboratory infrastructure, equipment and supplies (US Dollars)"
"rcvd_mdrmgt","Expenditure and utilisation",,"Funding received for programme costs to treat drug-resistant TB (US Dollars)"
"rcvd_orsrvy","Expenditure and utilisation",,"Funding received for operational research and surveys (US Dollars)"
"rcvd_oth","Expenditure and utilisation",,"Funding received for all other budget line items (US Dollars)"
"rcvd_patsup","Expenditure and utilisation",,"Funding received for patient support (US Dollars)"
"rcvd_prog","Expenditure and utilisation",,"Funding received for programme costs to treat drug-susceptible TB (US Dollars)"
"rcvd_sld","Expenditure and utilisation",,"Funding received for drugs to treat drug-resistant TB (US Dollars)"
"rcvd_staff","Expenditure and utilisation",,"Funding received for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars)"
"rcvd_tbhiv","Expenditure and utilisation",,"Funding received for collaborative TB/HIV activities (US Dollars)"
"rcvd_tot","Expenditure and utilisation",,"Total funding received for all budget line items (US Dollars)"
"rcvd_tot_domestic","Expenditure and utilisation",,"Funding received from domestic sources, including loans (US Dollars)"
"rcvd_tot_gf","Expenditure and utilisation",,"Funding received from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)"
"rcvd_tot_grnt","Expenditure and utilisation",,"Funding received from other sources (US Dollars)"
"rcvd_tot_sources","Expenditure and utilisation",,"Total funding received from all sources (US Dollars)"
"rcvd_tot_usaid","Expenditure and utilisation",,"Funding received from USAID (US Dollars)"
"rcvd_tpt","Expenditure and utilisation",,"Funding received for drugs for TB preventive treatment (US Dollars)"
"collab_private_lab","Laboratories","0=No; 1=yes","Were any non-NTP laboratories in the private sector (including NGOs) collaborating with the NTP?"
"collab_public_lab","Laboratories","0=No; 1=yes","Were any non-NTP laboratories in the public sector collaborating with the NTP?"
"culture","Laboratories",,"Number of sites providing TB diagnostic services using culture at the end of the reporting year"
"culture_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using culture that demonstrated proficiency by panel testing in the reporting year"
"dst","Laboratories",,"Number of sites providing phenotypic drug susceptibility testing for first-line drugs only at the end of the reporting year"
"dst_bdq","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for bedaquiline at the end of the reporting year"
"dst_bdq_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for bedaquiline that demonstrated proficiency by panel testing in the reporting year"
"dst_eqa_pass","Laboratories",,"Number of sites providing phenotypic drug susceptibility testing for first-line drugs only that demonstrated proficiency by panel testing"
"dst_inh","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for isoniazid at the end of the reporting year"
"dst_inh_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for isoniazid that demonstrated proficiency by panel testing in the reporting year"
"dst_lzd","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for linezolid at the end of the reporting year"
"dst_lzd_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for linezolid that demonstrated proficiency by panel testing in the reporting year"
"dst_moxlev","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for moxifloxacin and/or levofloxacin at the end of the reporting year"
"dst_moxlev_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for moxifloxacin and/or levofloxacin that demonstrated proficiency by panel testing in the reporting year"
"dst_naat_pza","Laboratories",,"Number of sites providing TB diagnostic services using drug susceptibility testing for pyrazinamide at the end of the reporting year"
"dst_pza","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for pyrazinamide at the end of the reporting year"
"dst_pza_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for pyrazinamide that demonstrated proficiency by panel testing in the reporting year"
"dst_rif","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for rifampicin at the end of the reporting year"
"dst_rif_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for rifampicin that demonstrated proficiency by panel testing in the reporting year"
"dx_test_sites","Laboratories",,"Total number of sites providing laboratory diagnostic testing for TB at the end of the reporting year"
"igra_used","Laboratories","0=No; 1=yes; 3=Don’t know","Were Interferon Gamma Release Assays (IGRA) used as tests of TB infection in the public or private sector before starting TB preventive treatment for any population at risk"
"infection_tests_used","Laboratories","3=Don’t know; 175=Interferon Gamma Release Assays (IGRA); 176=Tuberculin Skin Test (TST); 177=IGRA and TST; 194=Not used","Tests of TB infection used in the public or private sector before starting TB preventive treatment for any population at risk"
"iso15189_accredited","Laboratories",,"Number of sites with ISO15189 accreditation by the end of the reporting year"
"lab_cul","Laboratories",,"Number of laboratories providing TB diagnostic services using culture"
"lab_dst","Laboratories",,"Number of laboratories providing TB diagnostic services using drug susceptibility testing"
"lab_dst_eqa","Laboratories",,"Number of drug susceptibility testing laboratories for which External Quality Assessment (EQA) was carried out"
"lab_dst_eqa_pass","Laboratories",,"Number of drug susceptibility testing laboratories which demonstrated acceptable performance"
"lab_lpa","Laboratories",,"Number of laboratories providing TB diagnostic services using Line Probe Assay (LPA) rifampicin"
"lab_lpa_eqa","Laboratories",,"Number of Line Probe Assay (LPA) rifampicin  laboratories for which External Quality Assessment (EQA) was carried out"
"lab_lpa_eqa_pass","Laboratories",,"Number of Line Probe Assay (LPA) rifampicin laboratories which demonstrated acceptable performance"
"lab_sm","Laboratories",,"Number of laboratories providing TB diagnostic services using smear microscopy"
"lab_sm_eqa","Laboratories",,"Number of smear microscopy laboratories for which External Quality Assessment (EQA) was carried out"
"lab_sm_eqa_pass","Laboratories",,"Number of smear microscopy laboratories which demonstrated acceptable performance"
"lab_sm_led","Laboratories",,"Number of laboratories providing TB diagnostic services using LED microscopes for smear microscopy"
"lab_xpert","Laboratories",,"Number of laboratories providing TB diagnostic services using xpert MTB/RIF"
"lab_xpert_eqa","Laboratories",,"Number of laboratories providing TB diagnostic services using xpert MTB/RIF for which External Quality Assessment (EQA) was carried out"
"lmis","Laboratories",,"Number of sites which by the end of the reporting year record TB specimen reception and test results in a formal computer-based laboratory information system"
"lpa","Laboratories",,"Number of sites providing Line Probe Assay services at the end of the reporting year"
"lpa_eqa_pass","Laboratories",,"Number of sites providing Line Probe Assay services that demonstrated proficiency by panel testing"
"lpa_fl","Laboratories",,"Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for first line drugs (both rifampicin and isoniazid) at the end of the reporting year"
"lpa_fl_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for first line drugs (both rifampicin and isoniazid) that demonstrated proficiency by panel testing in the reporting year"
"lpa_sl","Laboratories",,"Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for second line drugs (fluoroquinolones) at the end of the reporting year"
"lpa_sl_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for second line drugs (fluoroquinolones) that demonstrated proficiency by panel testing in the reporting year"
"m_fq","Laboratories",,"Number of sites providing TB diagnostic services using molecular tests for detection of fluoroquinolone resistance at the end of the reporting year"
"m_inh","Laboratories",,"Number of sites providing TB diagnostic services using molecular tests for detection of isoniazid resistance at the end of the reporting year"
"m_wrd","Laboratories",,"Number of sites providing TB diagnostic services using molecular WHO-recommended rapid diagnostics at the end of the reporting year"
"m_wrd_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using molecular WHO-recommended rapid diagnostics that demonstrated proficiency by panel testing in the reporting year"
"m_wrd_etrans","Laboratories",,"Number of sites using molecular WHO-recommended rapid diagnostics reported in variable m_wrd which by the end of the reporting year transmit results automatically to clinicians and to an information management system"
"m_wrd_tests_performed","Laboratories",,"Total number of diagnostic tests performed using molecular WHO-recommended rapid diagnostics"
"m_wrd_tests_positive","Laboratories",,"Number of positive results among the diagnostic tests performed using molecular WHO-recommended rapid diagnostics"
"nrl","Laboratories","0=No; 1=yes","Was there a national reference laboratory or laboratories (NRL)?"
"nrl_iso15189","Laboratories","0=No; 1=yes","Has the national reference laboratory (or national reference laboratories) achieved national or international accreditation according to the ISO 15189 standard?"
"nrl_qms","Laboratories","0=No; 1=yes","Has a formal quality management system towards achieving laboratory accreditation been implemented at the National Reference Laboratory?"
"nrl_srl_link","Laboratories","0=No; 1=yes","Has a formal link been established between the National Reference Laboratory and a partner Supranational Reference Laboratory?"
"qms","Laboratories","0=No; 1=yes","Is a formal quality management system towards achieving accreditation being implemented in all laboratories conducting culture, LPA and/or DST?"
"qms_pending","Laboratories",,"Number of sites that by the end of the reporting year are not accredited and that are in the process of establishing a formal quality management system towards achieving accreditation"
"sldst","Laboratories",,"Number of sites providing phenotypic drug susceptibility testing for first-line drugs and second-line drugs at the end of the reporting year"
"sldst_avail_incntry","Laboratories","0=No; 1=yes","Was second-line drug susceptibility testing available within the country for TB National Treatment Programme patients?"
"sldst_avail_outcntry","Laboratories","0=No; 1=yes","Was second-line drug susceptibility testing available outside the country for TB National Treatment Programme patients?"
"sldst_eqa_pass","Laboratories",,"Number of sites providing phenotypic drug susceptibility testing for first-line drugs and second-line drugs that demonstrated proficiency by panel testing"
"sllpa","Laboratories",,"Number of sites providing Line Probe Assay (LPA) services for rifampicin, isoniazid, fluoroquinolones, second-line injectables"
"sllpa_eqa_pass","Laboratories",,"Number of sites providing Line Probe Assay (LPA) services for rifampicin, isoniazid, fluoroquinolones, second-line injectables that demonstrated proficiency by panel testing"
"smear","Laboratories",,"Number of sites providing TB diagnostic services using smear microscopy (including fluorescent) at the end of the reporting year"
"smear_eqa","Laboratories",,"Number of sites providing TB diagnostic services using smear microscopy covered by a comprehensive EQA system"
"smear_eqa_pass","Laboratories",,"Number of sites providing TB diagnostic services using smear microscopy (including fluorescent) that demonstrated proficiency by panel testing in the reporting year"
"tbst_used","Laboratories","0=No; 1=yes; 3=Don’t know","Were antigen-based skin tests (TBST) used as tests of TB infection in the public or private sector before starting TB preventive treatment for any population at risk"
"tst_used","Laboratories","0=No; 1=yes; 3=Don’t know","Were tuberculin skin tests (TST) used as tests of TB infection in the public or private sector before starting TB preventive treatment for any population at risk"
"xpert","Laboratories",,"Number of sites providing TB diagnostic services using Xpert MTB/RIF at the end of the reporting year"
"xpert_eqa","Laboratories",,"Number of sites providing TB diagnostic services using Xpert MTB/RIF covered by a comprehensive EQA system"
"xpert_etrans","Laboratories",,"Number of sites using Xpert MTB/RIF which transmit results automatically to clinicians and to an information management system"
"e_hh_contacts","Latent TB infection estimates",,"Estimated number of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease"
"e_hh_contacts_hi","Latent TB infection estimates",,"Estimated number of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease: High bound"
"e_hh_contacts_lo","Latent TB infection estimates",,"Estimated number of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease: Low bound"
"e_hh_size","Latent TB infection estimates",,"Estimated average household size"
"e_prevtx_eligible","Latent TB infection estimates",,"Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy"
"e_prevtx_eligible_hi","Latent TB infection estimates",,"Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy: high bound"
"e_prevtx_eligible_lo","Latent TB infection estimates",,"Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy: low bound"
"e_prevtx_hh_contacts_pct","Latent TB infection estimates",,"Estimated % of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease who were provided with TB preventive treatment"
"e_prevtx_hh_contacts_pct_hi","Latent TB infection estimates",,"Estimated % of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease who were provided with TB preventive treatment: High bound"
"e_prevtx_hh_contacts_pct_lo","Latent TB infection estimates",,"Estimated % of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease who were provided with TB preventive treatment: Low bound"
"e_prevtx_kids_pct","Latent TB infection estimates",,"Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy"
"e_prevtx_kids_pct_hi","Latent TB infection estimates",,"Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy: High bound"
"e_prevtx_kids_pct_lo","Latent TB infection estimates",,"Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy: Low bound"
"source_hh","Latent TB infection estimates",,"Source of estimate of average household size"
"tbhiv_sentin_cil","Non-routine HIV surveillance",,"Lower limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using sentinel sites"
"tbhiv_sentin_ciu","Non-routine HIV surveillance",,"Upper limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using sentinel sites"
"tbhiv_sentin_prev","Non-routine HIV surveillance",,"Prevalence (%) of HIV in TB patients estimated using sentinel sites"
"tbhiv_sentin_yr","Non-routine HIV surveillance",,"Year in which prevalence of HIV in TB patients was estimated using sentinel sites"
"tbhiv_surv_cil","Non-routine HIV surveillance",,"Lower limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using nationwide representative surveys"
"tbhiv_surv_ciu","Non-routine HIV surveillance",,"Upper limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using nationwide representative surveys"
"tbhiv_surv_prev","Non-routine HIV surveillance",,"Prevalence (%) of HIV in TB patients estimated using nationwide representative
surveys"
"tbhiv_surv_yr","Non-routine HIV surveillance",,"Year in which prevalence of HIV in TB patients was estimated using nationwide representative surveys"
"agegroup_option","Notification","220=all defined in 2013 reporting framework plus 4-9 10-14 15-19 20-24 age groups; 221=all; 222=all except for 5-9 and 10-14 age groups; 223=only 0-4 5-14 and 15+ age groups","The set of age groups by which notifications have been disaggregated"
"all_conf_xdr","Notification",,"Number of laboratory-confirmed XDR-TB cases identified in the current year (including in MDR cases diagnosed in previous years)."
"c_newinc","Notification",,"Total of new and relapse cases and cases with unknown previous TB treatment history"
"conf_mdr","Notification",,"Number of laboratory-confirmed MDR-TB cases identified"
"conf_mdr_tx","Notification",,"Number of laboratory-confirmed MDR-TB patients who started treatment for MDR-TB"
"conf_rr_fqr","Notification",,"Number of laboratory-confirmed TB cases that are resistant to rifampicin and resistant to any fluoroquinolone (pre-XDR-TB or XDR-TB)"
"conf_rr_fqr_tx","Notification",,"Number of patients with laboratory-confirmed resistance to rifampicin and resistance to any fluoroquinolone (i.e. with pre-XDR-TB or XDR-TB) who started treatment for pre-XDR-TB or XDR-TB."
"conf_rr_nfqr","Notification",,"Number of laboratory-confirmed TB cases with rifampicin resistance and with no known resistance to any fluoroquinolones"
"conf_rr_nfqr_tx","Notification",,"Number of patients with laboratory-confirmed resistance to rifampicin and with no known resistance to any fluoroquinolones who started treatment for MDR-TB. (This does not include patients treated for pre-XDR-TB or XDR-TB)."
"conf_rrmdr","Notification",,"Number of laboratory-confirmed RR-TB or MDR-TB cases identified"
"conf_rrmdr_tx","Notification",,"Number of laboratory-confirmed rifampicin-resistant (RR-TB) or multidrug-resistant TB (MDR-TB) patients who started treatment for MDR-TB"
"conf_xdr_tx","Notification",,"Number of laboratory-confirmed XDR-TB patients who started treatment for XDR-TB"
"hiv_all","Notification",,"Total number of people who are on antiretroviral therapy"
"hiv_all_tpt","Notification",,"Total number of people who are on antiretroviral therapy and who started TB preventive treatment"
"hiv_all_tpt_completed","Notification",,"Number of people on antiretroviral therapy who completed TB preventive treatment (TPT) among those who initiated any course of TPT"
"hiv_all_tpt_started","Notification",,"Number of people on antiretroviral therapy who initiated any course of TB preventive treatment"
"hiv_art","Notification",,"HIV-positive TB patients started or continued on antiretroviral therapy (ART)"
"hiv_cpt","Notification",,"HIV-positive TB patients started or continued on co-trimoxazole preventive therapy (CPT)"
"hiv_elig_all","Notification",,"Total number of people who are on antiretroviral therapy and who are eligible for TB preventive treatment (TPT)"
"hiv_elig_all_tpt","Notification",,"Total number of people who are on antiretroviral therapy and eligible for TB preventive treatment (TPT) who started TPT"
"hiv_elig_new","Notification",,"Total number of people who started antiretroviral therapy in the last 12 months and who are eligible for TB preventive treatment (TPT)"
"hiv_elig_new_tpt","Notification",,"Total number of people who started antiretroviral therapy in the last 12 months and eligible for TB preventive treatment (TPT) who started TPT"
"hiv_ipt","Notification",,"People living with HIV newly enrolled in HIV treatment who started treatment for latent TB infection"
"hiv_ipt_reg_all","Notification",,"People living with HIV currently enrolled in HIV treatment who started treatment for latent TB infection"
"hiv_new","Notification",,"Total number of people who started antiretroviral therapy in the last 12 months"
"hiv_new_tpt","Notification",,"Total number of people who started antiretroviral therapy in the last 12 months and who started TB preventive treatment"
"hiv_reg","Notification",,"Total number of people registered as HIV-positive regardless of year of diagnosis. (Total number of adults and children enrolled in HIV care; includes everyone in the HIV care and/or ART register)"
"hiv_reg_all","Notification",,"Number of adults and children currently enrolled in HIV treatment during the year."
"hiv_reg_new","Notification",,"Number of adults and children newly enrolled in HIV treatment  (i.e. those who registered for antiretroviral therapy) during the reporting period"
"hiv_reg_new2","Notification",,"Total number of adults and children newly enrolled in HIV treatment  (i.e. those who registered for antiretroviral therapy) during the reporting period"
"hiv_tbdetect","Notification",,"Total number of adults and children newly enrolled in HIV treatment who are diagnosed as having active TB disease during the reporting period"
"hiv_tbscr","Notification",,"Number of adults and children enrolled in HIV care who had their TB status assessed and recorded during their last visit"
"hivtest","Notification",,"TB patients (new and re-treatment) with an HIV test result recorded in the TB register"
"hivtest_pos","Notification",,"TB patients (new and re-treatment) recorded as HIV-positive"
"mdr_alloral_short_tx","Notification","0=No; 1=Yes; 3=Don't know","Number of patients started on all oral shorter MDR-TB treatment regimens during the reporting year"
"mdr_alloral_short_used","Notification","0=No; 1=Yes; 3=Don't know","Had any patients been started on all oral shorter MDR-TB treatment regimens by the end of the reporting year?"
"mdr_shortreg_tx","Notification",,"Number of patients started on shorter MDR-TB treatment regiments during the reporting year"
"mdr_shortreg_used","Notification","0=No; 1=Yes; 3=Don't know","Had any patients been started on shorter MDR-TB treatment regimens by the end of the reporting year?"
"mdr_tx_adsm","Notification",,"Number of patients who started treatment for MDR-TB/pre-XDR-TB/XDR-TB in the reporting year who are also being actively monitored for adverse events"
"mdr_tx_adverse_events","Notification",,"Number of patients on MDR-TB treatment who had adverse events registered in the reporting year"
"mdrxdr_alloral_tx","Notification",,"Number of patients started on all oral longer MDR-TB treatment regimens during the reporting year"
"mdrxdr_alloral_used","Notification","0=No; 1=Yes; 3=Don't know","Had any patients been started on all oral longer MDR-TB treatment regimens by the end of reporting year?"
"mdrxdr_bdq_tx","Notification",,"Number of patients started on Bedaquiline during the reporting year"
"mdrxdr_bdq_used","Notification","0=No; 1=Yes; 3=Don't know","Had any TB patients been started on Bedaquiline for the treatment of MDR-TB/pre-XDR-TB/XDR-TB by the end of reporting year?"
"mdrxdr_bpalm_tx","Notification",,"Number of patients started on the all-oral BPaLM/BPaL regimen for the treatment of MDR/RR-TB or pre-XDR-TB during the reporting year?"
"mdrxdr_bpalm_used","Notification","0=No; 1=Yes; 3=Don't know","Had any patients been started on the all-oral BPaLM/BPaL regimen for the treatment of MDR/RR-TB or, pre-XDR-TB  by the end of reporting year?"
"mdrxdr_dlm_tx","Notification",,"Number of patients started on Delamanid during the reporting year"
"mdrxdr_dlm_used","Notification","0=No; 1=Yes; 3=Don't know","Had any TB patients been started on Delamanid for the treatment of MDR-/XDR-TB by the end of reporting as part of expanded access, compassionate use or under normal programmatic use, whether in the public or private sector?"
"new_clindx","Notification",,"New pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician or another medical practitioner who has decided to give the patient a full course of TB treatment).  It also includes pulmonary clinically diagnosed cases with unknown previous TB treatment history."
"new_ep","Notification",,"New extrapulmonary cases (bacteriologically confirmed or clinically diagnosed). As of 2013 this also includes extrapulmonary cases with unknown previous TB treatment history."
"new_ep_f014","Notification",,"New extrapulmonary cases: females aged 0-14 years (not used after 2012)"
"new_ep_f04","Notification",,"New extrapulmonary cases: females aged 0-4 years (not used after 2012)"
"new_ep_f1524","Notification",,"New extrapulmonary cases: females aged 15-24 years (not used after 2012)"
"new_ep_f15plus","Notification",,"New extrapulmonary cases: females aged 15 years and over (not used after 2012)"
"new_ep_f2534","Notification",,"New extrapulmonary cases: females aged 25-34 years (not used after 2012)"
"new_ep_f3544","Notification",,"New extrapulmonary cases: females aged 35-44 years (not used after 2012)"
"new_ep_f4554","Notification",,"New extrapulmonary cases: females aged 45-54 years (not used after 2012)"
"new_ep_f514","Notification",,"New extrapulmonary cases: females aged 5-14 years (not used after 2012)"
"new_ep_f5564","Notification",,"New extrapulmonary cases: females aged 55-64 years (not used after 2012)"
"new_ep_f65","Notification",,"New extrapulmonary cases: females aged 65 years and over (not used after 2012)"
"new_ep_fu","Notification",,"New extrapulmonary cases: females age unknown (not used after 2012)"
"new_ep_m014","Notification",,"New extrapulmonary cases: males aged 0-14 years (not used after 2012)"
"new_ep_m04","Notification",,"New extrapulmonary cases: males aged 0-4 years (not used after 2012)"
"new_ep_m1524","Notification",,"New extrapulmonary cases: males aged 15-24 years (not used after 2012)"
"new_ep_m15plus","Notification",,"New extrapulmonary cases: males aged 15 years and over (not used after 2012)"
"new_ep_m2534","Notification",,"New extrapulmonary cases: males aged 25-34 years (not used after 2012)"
"new_ep_m3544","Notification",,"New extrapulmonary cases: males aged 35-44 years (not used after 2012)"
"new_ep_m4554","Notification",,"New extrapulmonary cases: males aged 45-54 years (not used after 2012)"
"new_ep_m514","Notification",,"New extrapulmonary cases: males aged 5-14 years (not used after 2012)"
"new_ep_m5564","Notification",,"New extrapulmonary cases: males aged 55-64 years (not used after 2012)"
"new_ep_m65","Notification",,"New extrapulmonary cases: males aged 65 years and over (not used after 2012)"
"new_ep_mu","Notification",,"New extrapulmonary cases: males age unknown (not used after 2012)"
"new_ep_sexunk014","Notification",,"New extrapulmonary cases: sex unknown, aged 0-14 years (not used after 2012)"
"new_ep_sexunk04","Notification",,"New extrapulmonary cases: sex unknown, aged 0-4 years (not used after 2012)"
"new_ep_sexunk15plus","Notification",,"New extrapulmonary cases: sex unknown, aged 15 years and over (not used after 2012)"
"new_ep_sexunk514","Notification",,"New extrapulmonary cases: sex unknown, aged 5-14 years (not used after 2012)"
"new_ep_sexunkageunk","Notification",,"New extrapulmonary cases: sex unknown, age unknown (not used after 2012)"
"new_labconf","Notification",,"New pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics such as Xpert MTB/RIF). As of 2013 this also includes pulmonary bacteriologically confirmed cases with unknown previous TB treatment history."
"new_oth","Notification",,"Other new cases (not used after 2012)"
"new_sn","Notification",,"New pulmonary smear-negative cases (not used after 2012)"
"new_sn_f014","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 0-14 years (not used after 2012)"
"new_sn_f04","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 0-4 years (not used after 2012)"
"new_sn_f1524","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 15-24 years (not used after 2012)"
"new_sn_f15plus","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 15 years and over (not used after 2012)"
"new_sn_f2534","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 25-34 years (not used after 2012)"
"new_sn_f3544","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 35-44 years (not used after 2012)"
"new_sn_f4554","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 45-54 years (not used after 2012)"
"new_sn_f514","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 5-14 years (not used after 2012)"
"new_sn_f5564","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 55-64 years (not used after 2012)"
"new_sn_f65","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females aged 65 years and over (not used after 2012)"
"new_sn_fu","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: females age unknown (not used after 2012)"
"new_sn_m014","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 0-14 years (not used after 2012)"
"new_sn_m04","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 0-4 years (not used after 2012)"
"new_sn_m1524","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 15-24 years (not used after 2012)"
"new_sn_m15plus","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 15 years and above (not used after 2012)"
"new_sn_m2534","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 25-34 years (not used after 2012)"
"new_sn_m3544","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 35-44 years (not used after 2012)"
"new_sn_m4554","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 45-54 years (not used after 2012)"
"new_sn_m514","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 5-14 years (not used after 2012)"
"new_sn_m5564","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 55-64 years (not used after 2012)"
"new_sn_m65","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males aged 65 years and over (not used after 2012)"
"new_sn_mu","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: males age unknown (not used after 2012)"
"new_sn_sexunk014","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 0-14 years (not used after 2012)"
"new_sn_sexunk04","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 0-4 years (not used after 2012)"
"new_sn_sexunk15plus","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 15 years and over (not used after 2012)"
"new_sn_sexunk514","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 5-14 years (not used after 2012)"
"new_sn_sexunkageunk","Notification",,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, age unknown (not used after 2012)"
"new_sp","Notification",,"New pulmonary smear-positive cases (not used after 2012)"
"new_sp_f014","Notification",,"New pulmonary smear positive cases: females aged 0-14 years (not used after 2012)"
"new_sp_f04","Notification",,"New pulmonary smear positive cases: females aged 0-4 years (not used after 2012)"
"new_sp_f1524","Notification",,"New pulmonary smear positive cases: females aged 15-24 years (not used after 2012)"
"new_sp_f2534","Notification",,"New pulmonary smear positive cases: females aged 25-34 years (not used after 2012)"
"new_sp_f3544","Notification",,"New pulmonary smear positive cases: females aged 35-44 years (not used after 2012)"
"new_sp_f4554","Notification",,"New pulmonary smear positive cases: females aged 45-54 years (not used after 2012)"
"new_sp_f514","Notification",,"New pulmonary smear positive cases: females aged 5-14 years (not used after 2012)"
"new_sp_f5564","Notification",,"New pulmonary smear positive cases: females aged 55-64 years (not used after 2012)"
"new_sp_f65","Notification",,"New pulmonary smear positive cases: females aged 65 and over (not used after 2012)"
"new_sp_fu","Notification",,"New pulmonary smear positive cases: females age unknown (not used after 2012)"
"new_sp_m014","Notification",,"New pulmonary smear positive cases: males aged 0-14 years (not used after 2012)"
"new_sp_m04","Notification",,"New pulmonary smear positive cases: males aged 0-4 years (not used after 2012)"
"new_sp_m1524","Notification",,"New pulmonary smear positive cases: males aged 15-24 years (not used after 2012)"
"new_sp_m2534","Notification",,"New pulmonary smear positive cases: males aged 25-34 years (not used after 2012)"
"new_sp_m3544","Notification",,"New pulmonary smear positive cases: males aged 35-44 years (not used after 2012)"
"new_sp_m4554","Notification",,"New pulmonary smear positive cases: males aged 45-54 years (not used after 2012)"
"new_sp_m514","Notification",,"New pulmonary smear positive cases: males aged 5-14 years (not used after 2012)"
"new_sp_m5564","Notification",,"New pulmonary smear positive cases: males aged 55-64 years (not used after 2012)"
"new_sp_m65","Notification",,"New pulmonary smear positive cases: males aged 65 years and over (not used after 2012)"
"new_sp_mu","Notification",,"New pulmonary smear positive cases: males age unknown (not used after 2012)"
"new_su","Notification",,"New pulmonary smear unknown/not done cases"
"newinc_ep_rdx","Notification",,"(if rdx_data_available=62) Number of new and relapse extrapulmonary cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)"
"newinc_pulm_clindx_rdx","Notification",,"(if rdx_data_available=62) Number of new and relapse pulmonary clinically diagnosed cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)"
"newinc_pulm_labconf_rdx","Notification",,"(if rdx_data_available=62) Number of new and relapse pulmonary bacteriologically confirmed cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)"
"newinc_rdx","Notification",,"(if rdx_data_available=60) Number of new and relapse cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)"
"newrel_art","Notification",,"HIV-positive new and relapse (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients started or continued on antiretroviral therapy"
"newrel_art_014","Notification",,"Number of HIV-positive new and relapse TB patients aged 0-14 years who started or continued on antiretroviral therapy"
"newrel_f014","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 0-14 years"
"newrel_f04","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 0-4 years"
"newrel_f1014","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 10-14 years"
"newrel_f1519","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15-19 years"
"newrel_f1524","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15-24 years"
"newrel_f15plus","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15 years and over"
"newrel_f2024","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 20-24 years"
"newrel_f2534","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 25-34 years"
"newrel_f3544","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 35-44 years"
"newrel_f4554","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 45-54 years"
"newrel_f514","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 5-14 years"
"newrel_f5564","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 55-64 years"
"newrel_f59","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 5-9 years"
"newrel_f65","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 65 years and over"
"newrel_fu","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females age unknown"
"newrel_hivpos","Notification",,"Number of new and relapse  (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients recorded as HIV-positive"
"newrel_hivpos_014","Notification",,"Number of new and relapse TB patients aged 0-14 years recorded as HIV-positive"
"newrel_hivtest","Notification",,"Number of new and relapse (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis"
"newrel_hivtest_014","Notification",,"Number of new and relapse TB patients aged 0-14 years tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis"
"newrel_m014","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 0-14 years"
"newrel_m04","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 0-4 years"
"newrel_m1014","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 10-14 years"
"newrel_m1519","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15-19 years"
"newrel_m1524","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15-24 years"
"newrel_m15plus","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15 years and over"
"newrel_m2024","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 20-24 years"
"newrel_m2534","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 25-34 years"
"newrel_m3544","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 35-44 years"
"newrel_m4554","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 45-54 years"
"newrel_m514","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 5-14 years"
"newrel_m5564","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 55-64 years"
"newrel_m59","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 5-9 years"
"newrel_m65","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 65 years and over"
"newrel_mu","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males age unknown"
"newrel_sexunk014","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 0-14 years"
"newrel_sexunk04","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 0-4 years"
"newrel_sexunk15plus","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 15 years and over"
"newrel_sexunk514","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 5-14 years"
"newrel_sexunkageunk","Notification",,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, age unknown"
"newrel_tbhiv_flg","Notification","0=No; 1=Yes.","Are data on HIV testing, HIV positivity and provision of antiretroviral therapy (ART) restricted to new and relapse TB cases only?"
"newret_oth","Notification",,"Other cases not included in new and re-treatment case numbers"
"notif_foreign","Notification",,"New and re-treatment TB cases among foreign-born individuals"
"nrr","Notification",,"Number of TB cases with no evidence of rifampicin resistance (either rifampicin susceptible or tests for susceptibility to rifampicin not done)"
"nrr_hpmz_tx","Notification",,"Number of patients started on the 4-month HPMZ regimen for the treatment of rifampicin-susceptible TB during the reporting year?"
"nrr_hpmz_used","Notification","0=No; 1=Yes; 3=Don't know","Had any patients been started on the 4-month HPMZ regimen for the treatment of rifampicin-susceptible TB by the end of reporting year?"
"nrr_tx","Notification",,"Number of TB cases with no evidence of rifampicin resistance (either rifampicin susceptible or tests for susceptibility to rifampicin not done) started on a regimen to treat rifampicin-susceptible TB"
"rdst_new","Notification",,"Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: new cases"
"rdst_ret","Notification",,"Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: previously treated cases"
"rdst_unk","Notification",,"Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: cases with unknown previous TB treatment history"
"rdx_data_available","Notification","0=No; 60= Yes available from the routine surveillance system; 61=Yes estimated from a review of a random sample of medical records; 62= Yes available from the routine surveillance system disaggregated by case type","Are data available on the number of new and relapse cases tested using a WHO-recommended rapid diagnostic during the reporting year?"
"rdxsurvey_newinc","Notification",,"(if rdx_data_available=61) Number of new and relapse cases whose medical records or treatment cards were included in the survey"
"rdxsurvey_newinc_rdx","Notification",,"(if rdx_data_available=61) Among the cases reported in rdxsurvey_newinc the number tested using a WHO-recommended rapid diagnostic (such as Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result)"
"rel_in_agesex_flg","Notification","0=No; 1=Yes.","Are all relapse cases included with new cases in the disaggregations by age and sex?"
"ret_nrel","Notification",,"Previously treated patients, excluding relapse cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed)"
"ret_oth","Notification",,"Other re-treatment cases"
"ret_rel","Notification",,"Relapse cases"
"ret_rel_clindx","Notification",,"Relapse pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician or another medical practitioner who has decided to give the patient a full course of TB treatment)."
"ret_rel_ep","Notification",,"Relapse extrapulmonary cases (bacteriologically confirmed or clinically diagnosed)"
"ret_rel_labconf","Notification",,"Relapse  pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics such as Xpert MTB/RIF)."
"ret_tad","Notification",,"Treatment after default cases"
"ret_taf","Notification",,"Treatment after failure cases"
"rr_nfqr_014_tx","Notification",,"The number of children aged 0-14 years among patients who started treatment for MDR/RR-TB"
"rr_sldst","Notification",,"Number of laboratory-confirmed RR-TB or MDR-TB cases tested for susceptibility to second-line drugs (fluoroquinolones and second-line injectable agents)"
"rrmdr_014_tx","Notification",,"The number of children aged 0-14 years among patients who started treatment for MDR-TB (regardless of whether rifampicin resistance was confirmed)"
"tbhiv_014_flg","Notification","0=No; 1=Yes.","Are data on TB/HIV indicators available for new and relapse TB patients that are children aged 0-14 years?"
"unconf_mdr_tx","Notification",,"Number of MDR-TB (not laboratory-confirmed) patients who started treatment for MDR-TB"
"unconf_rr_nfqr_tx","Notification",,"Number of patients (not laboratory-confirmed as having resistance to rifampicin and with no known resistance to any fluoroquinolones) who started treatment for MDR-TB. (This does not include patients treated for pre-XDR-TB or XDR-TB)."
"unconf_rrmdr_tx","Notification",,"Number of patients (not laboratory-confirmed as having rifampicin-resistant (RR-TB) or multidrg-resistant TB (MDR-TB)) who started treatment for MDR-TB"
"c_new_snep_tsr","Outcomes",,"Treatment success rate for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases, percent  (not used after 2011)"
"c_new_sp_tsr","Outcomes",,"Treatment success rate for new pulmonary smear-positive (and/or culture-positive) cases, percent  (not used after 2011)"
"c_new_tsr","Outcomes",,"Treatment success rate for all new cases (including relapse cases if rel_with_new_flg = 1), percent"
"c_ret_tsr","Outcomes",,"Treatment success rate for re-treatment cases (excluding relapse cases if rel_with_new_flg = 1), percent"
"c_tbhiv_tsr","Outcomes",,"Treatment success rate for HIV-positive TB cases, percent"
"hiv_new_snep_cmplt","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: completed  (not used after 2011)"
"hiv_new_snep_coh","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: cohort size  (not used after 2011)"
"hiv_new_snep_def","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: defaulted  (not used after 2011)"
"hiv_new_snep_died","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: died  (not used after 2011)"
"hiv_new_snep_fail","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: failed (not used after 2011)"
"hiv_new_sp_cmplt","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: completed (not used after 2011)"
"hiv_new_sp_coh","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: cohort size (not used after 2011)"
"hiv_new_sp_cur","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: cured (not used after 2011)"
"hiv_new_sp_def","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: defaulted (not used after 2011)"
"hiv_new_sp_died","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: died (not used after 2011)"
"hiv_new_sp_fail","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: failed (not used after 2011)"
"hiv_ret_cmplt","Outcomes",,"Outcomes for re-treatment HIV-positive TB cases: completed (not used after 2011)"
"hiv_ret_coh","Outcomes",,"Outcomes for re-treatment HIV-positive TB cases: cohort size (not used after 2011)"
"hiv_ret_cur","Outcomes",,"Outcomes for re-treatment HIV-positive TB cases: cured (not used after 2011)"
"hiv_ret_def","Outcomes",,"Outcomes for re-treatment HIV-positive TB cases: defaulted (not used after 2011)"
"hiv_ret_died","Outcomes",,"Outcomes for re-treatment HIV-positive TB cases: died (not used after 2011)"
"hiv_ret_fail","Outcomes",,"Outcomes for re-treatment HIV-positive TB cases: failed (not used after 2011)"
"mdr_coh","Outcomes",,"Outcomes for MDR-TB cases: cohort size"
"mdr_died","Outcomes",,"Outcomes for MDR-TB cases: died"
"mdr_fail","Outcomes",,"Outcomes for MDR-TB cases: treatment failed"
"mdr_lost","Outcomes",,"Outcomes for MDR-TB cases: lost to follow-up"
"mdr_succ","Outcomes",,"Outcomes for MDR-TB cases: treatment success (Cured or treatment completed)"
"new_snep_cmplt","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: completed (not used after 2011)"
"new_snep_coh","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: cohort size (not used after 2011)"
"new_snep_def","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: defauled (not used after 2011)"
"new_snep_died","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: died (not used after 2011)"
"new_snep_fail","Outcomes",,"Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: failed (not used after 2011)"
"new_sp_cmplt","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: completed (not used after 2011)"
"new_sp_coh","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: cohort size (not used after 2011)"
"new_sp_cur","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: cured (not used after 2011)"
"new_sp_def","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: defaulted (not used after 2011)"
"new_sp_died","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: died (not used after 2011)"
"new_sp_fail","Outcomes",,"Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: failed (not used after 2011)"
"newrel_coh","Outcomes",,"Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): cohort size"
"newrel_died","Outcomes",,"Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): died"
"newrel_fail","Outcomes",,"Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): treatment failed"
"newrel_lost","Outcomes",,"Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): lost to follow-up"
"newrel_succ","Outcomes",,"Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): treatment success (cured or treatment completed)"
"rel_with_new_flg","Outcomes","0=No; 1=Yes;","Are outcomes of relapse cases included in the newrel outcome variables?"
"rep_meth","Outcomes","100=smear;101=culture;102=smear or culture;","Method of confirmation used to report treatment outcomes of pulmonary cases  (not used after 2011)"
"ret_cmplt","Outcomes",,"Outcomes for re-treatment cases: completed  (not used after 2011)"
"ret_coh","Outcomes",,"Outcomes for re-treatment cases: cohort size (not used after 2011)"
"ret_cur","Outcomes",,"Outcomes for re-treatment cases: cured (not used after 2011)"
"ret_def","Outcomes",,"Outcomes for re-treatment cases: defaulted (not used after 2011)"
"ret_died","Outcomes",,"Outcomes for re-treatment cases: died (not used after 2011)"
"ret_fail","Outcomes",,"Outcomes for re-treatment cases: failed (not used after 2011)"
"ret_nrel_coh","Outcomes",,"Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): cohort size"
"ret_nrel_died","Outcomes",,"Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): died"
"ret_nrel_fail","Outcomes",,"Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): treatment failed"
"ret_nrel_lost","Outcomes",,"Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): lost to follow-up"
"ret_nrel_succ","Outcomes",,"Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): treatment success (cured or treatment completed)"
"tbhiv_coh","Outcomes",,"Outcomes for HIV-positive TB cases, all types: cohort size"
"tbhiv_died","Outcomes",,"Outcomes for HIV-positive TB cases, all types: died"
"tbhiv_fail","Outcomes",,"Outcomes for HIV-positive TB cases, all types: treatment failed"
"tbhiv_lost","Outcomes",,"Outcomes for HIV-positive TB cases, all types: lost to follow-up"
"tbhiv_succ","Outcomes",,"Outcomes for HIV-positive TB cases, all types: treatment success (cured or treatment completed)"
"used_2021_defs_flg","Outcomes","0=No; 1=Yes;","Are outcomes for both drug-susceptible and drug-resistant TB reported in line with the revised definitions published by WHO in April 2021 at https://www.who.int/publications/i/item/9789240022195?"
"xdr_coh","Outcomes",,"Outcomes for XDR-TB cases: cohort size"
"xdr_died","Outcomes",,"Outcomes for XDR-TB cases: number died"
"xdr_fail","Outcomes",,"Outcomes for XDR-TB cases: number whose treatment failed"
"xdr_lost","Outcomes",,"Outcomes for XDR-TB cases: lost to follow-up"
"xdr_succ","Outcomes",,"Outcomes for XDR-TB cases: treatment success (Cured or treatment completed)"
"coh","Outcomes by age group and sex",,"Outcomes: cohort size"
"cohort_type","Outcomes by age group and sex","newrel=new and relapse drug-susceptible TB treatment;","Cohort type"
"died","Outcomes by age group and sex",,"Outcomes: died"
"fail","Outcomes by age group and sex",,"Outcomes: treatment failed"
"lost","Outcomes by age group and sex",,"Outcomes:  lost to follow up"
"neval","Outcomes by age group and sex",,"Outcomes:  not evaluated"
"succ","Outcomes by age group and sex",,"Outcomes: treatment success (Cured or treatment completed)"
"tsr","Outcomes by age group and sex",,"Treatment success rate as a percentage"
"caseb_err_nat","Policies and services","0=No; 42=Yes (all TB patients in the country); 43=Yes (but only for MDR-TB patients countrywide); 44=Partially (transition to a case-based system is under way)","Did the National Treatment Programme keep (or have access to) an electronic case-based database for TB patients on treatment at national level"
"exp_res","Policies and services",,"National expenditure on tuberculosis research, excluding expenditure already reported in the finance section (US Dollars)"
"hcw_tb_infected","Policies and services",,"Number of health-care workers who had TB"
"hcw_tot","Policies and services",,"Total number of health-care workers who were working in the country in the public and private sector"
"m_01; m_02; etc.","Provisional notification",,"Month in the year for which notifications are reported. m_01 is the first month (January), m_02 is the second month (February), etc."
"q_1; q_2; etc.","Provisional notification",,"Quarter in the year for which notifications are reported. q_1 is the first quarter (January to March), q_2 is the second quarter (April to June), etc."
"report_coverage","Provisional notification","34=All units; 35=Some units","Indicates whether or not provisional data include data from all reporting units in the country"
"report_frequency","Provisional notification","70=Monthly; 71=Quarterly","Frequency at which provisional data are reported to WHO"
"priv_new_dx","Public-private mix",,"Number of new cases of TB diagnosed according to National Treatment Programme (NTP)  guidelines by private providers"
"pub_new_dx","Public-private mix",,"Number of new cases of TB diagnosed according to National Treatment Programme (NTP)  guidelines by non-NTP public providers"
"annual_report_published","UNHLM commitments","0=No; 1=yes","Does the National TB Programme (or equivalent) produce a publicly available annual report about the status of the TB epidemic and progress in response efforts?"
"cash_trans","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","(if social_protn=1) Are there conditional and/or unconditional cash-transfers?"
"enable_tx_adherence","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","(if social_protn=1) Are there enablers to adhere to TB treatment?"
"food_security","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","(if social_protn=1) Are there measures to ensure food security?"
"free_access_tbdx","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","(if social_protn=1) Is there free access to TB diagnostic testing (including all WHO-recommended rapid diagnostics  chest x-rays  culture or smear microscopy) for people with signs or symptoms presumptive of TB?"
"free_access_tbtx","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","(if social_protn=1) Is there free access to TB treatment and related medical services?"
"min_agg_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of agriculture or its equivalent  engaged in the national TB response?"
"min_def_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of defence or its equivalent  engaged in the national TB response?"
"min_dev_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of social development or its equivalent  engaged in the national TB response?"
"min_edu_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of education or its equivalent  engaged in the national TB response?"
"min_fin_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of finance or its equivalent  engaged in the national TB response?"
"min_jus_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of justice or its equivalent  engaged in the national TB response?"
"min_lab_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of labour or its equivalent  engaged in the national TB response?"
"min_tra_collab","UNHLM commitments","2=Not applicable; 6=Not engaged; 230=Advocacy information education and communication; 231=TB prevention and care; 232=Patient support including economic social or nutritional benefits","How is the ministry of transport or its equivalent  engaged in the national TB response?"
"ms_review","UNHLM commitments","0=No; 1=yes","Is there a national multi-sectoral and multi-stakeholder accountability and review mechanism under high-level leadership to monitor and review progress towards ending TB?"
"ms_review_civil_soc","UNHLM commitments","0=No; 1=yes","Do representatives of civil society and affected communities participate in the multi-sectoral accountability and review mechanism?"
"protect_association","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","Is freedom of association for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. no compulsory isolation because of a TB diagnosis)"
"protect_employment","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","Is employment for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. not being dismissed because of a TB diagnosis)"
"protect_housing","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","Is housing for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. not being evicted from housing facilities because of a TB diagnosis)"
"protect_movement","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","Is freedom of movement for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. no restriction to access any congregate setting or transit through any geographical area because of a TB diagnosis)"
"protect_parenting","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","Are parental rights for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. not having parental rights over children affected in any way as a result of TB diagnosis of a parent)"
"social_protn","UNHLM commitments","0=No; 1=Yes; 3=Don't know;","Is there a national policy to specifically provide social protection services to TB-affected individuals?"
"ep_spec_available","Zoonotic TB","0=No; 1=Yes; 2=Not applicable","Are data available on the number of bacteriologically confirmed extrapulmonary TB cases with test results for the speciation of the Mycobacterium tuberculosis complex in the reporting year?"
"newrel_ep_labconf","Zoonotic TB",,"(if ep_spec_available=1) Among the new and relapse extrapulmonary TB cases reported in new_ep and ret_rel_ep, the number of cases that were bacteriologically confirmed, i.e. by culture or molecular technologies"
"newrel_ep_mbovis","Zoonotic TB",,"(if ep_spec_available=1) Among extrapulmonary TB cases with test results for speciation reported in newrel_ep_spec, number of cases identified as having Mycobacterium bovis"
"newrel_ep_spec","Zoonotic TB",,"(if ep_spec_available=1) Among bacteriologically confirmed extrapulmonary TB cases reported in newrel_ep_labconf, number of cases with test results for the speciation of the Mycobacterium tuberculosis complex"
"newrel_pulm_mbovis","Zoonotic TB",,"(if pulm_spec_available=1) Among pulmonary cases with test results for speciation reported in newrel_pulm_spec, number of cases identified as having Mycobacterium bovis"
"newrel_pulm_spec","Zoonotic TB",,"(if pulm_spec_available=1) Among bacteriologically confirmed new and relapse pulmonary TB cases, number of cases with test results for the speciation of the Mycobacterium tuberculosis complex"
"pulm_spec_available","Zoonotic TB","0=No; 1=Yes; 2=Not applicable","Are data available on the number of bacteriologically confirmed pulmonary TB cases with test results for the speciation of the Mycobacterium tuberculosis complex in the reporting year?"
